Showing 5511-5520 of 10820 results for "".
- Consumer Reports: One-Third of Tested Sunscreens Delivered Less Than Half of Labeled SPF Protectionhttps://practicaldermatology.com/news/consumer-reports-one-third-of-tested-sunscreens-delivered-less-than-half-of-labeled-spf-protection/2458180/For the fifth year in a row, Consumer Reports’ testing has shown that some sunscreens failed to provide the level of protection promised on the package. Of the more than 60 lotions,&nb
- Valeant Dermatology Announces New Senior Leadership Team in Advance of SILIQ Launchhttps://practicaldermatology.com/news/valeant-dermatology-announces-new-senior-leadership-team-in-advance-of-siliq-launch/2458182/Valeant Dermatology announced a new senior leadership team, led by Bill Humphries, executive vice president and group chairman. The team includes Michael McMyne, vice president of sales; Stacey Williams, vice president of marketing; Charles Hahn,
- FDA Accepts Aclaris Therapeutics' NDA for Topical Treatment of Seborrheic Keratosishttps://practicaldermatology.com/news/fda-accepts-aclaris-therapeutics-nda-for-topical-treatment-of-seborrheic-keratosis/2458188/The FDA has accepted Aclaris Therapeutics' New Drug Application (NDA) for A-101 40% topical solution, an investigational drug for the potential treatment of seborrheic keratosis (SK). The NDA acceptance by the FDA in its 74-day letter indicates that the application is sufficiently complete to
- Alastin to Present Study Results Demonstrating Anti-aging and Procedure Enhancement Results of TriHex Technologyhttps://practicaldermatology.com/news/alastin-to-present-study-results-demonstrating-effectiveness-of-trihex-technology-for-post-laser-treatment-care/2458197/Alastin Skincare, Inc. will present data on three new studies at the 7th Annual Summit in Aesthetic Medicine meeting in Newport Beach, CA (May 5-7, 2017). "As part of our commitment to generate scientific data related to our Alastin Skincare products and technology, we have been work
- Pfizer Announces U.S. FDA Filing Acceptance of Supplemental New Drug Application for XELJANZ® (tofacitinib citrate) for the Treatment of Adult Patients with Active Psoriatic Arthritishttps://practicaldermatology.com/news/pfizer-announces-us-fda-filing-acceptance-of-supplemental-new-drug-application-for-xeljanz-tofacitinib-citrate-for-the-treatment-of-adult-patients-wit/2458195/(via BusinessWire) Pfizer Inc. announced today that the United States Food and Drug Administration (FDA) has accepted for rev
- Abeona Therapeutics Provides Update on EB-101 Gene Therapy for Severe Form of Epidermolysis Bullosahttps://practicaldermatology.com/news/abeona-therapeutics-provides-update-on-eb-101-gene-therapy-for-severe-form-of-epidermolysis-bullosa/2458202/Abeona Therapeutics, Inc. has announced updated clinical data from the ongoing Phase 1/2 clinical trial for the EB-101 gene therapy program for patients with Recessive Dystrophic Epidermolysis Bullosa (RDEB), a severe fo
- BioPharmX Completes Phase 2b Trial of BPX-01; Topline Results Coming Soonhttps://practicaldermatology.com/news/biopharmx-completes-phase-2b-trial-of-bpx-01-topline-results-coming-soon/2458217/BioPharmX Corporation completed their last subject visit in a Phase 2b trial of their investigational acne drug, BPX-01, and the last site close-out visit was April 7, 2017. The company now plans to announce topline data from the trial in the fi
- Topical Cannabinoids May Soothe Itchy Skinhttps://practicaldermatology.com/news/topical-cannabinoids-may-soothe-itchy-skin/2458218/Cannabinoids contain anti-inflammatory properties that may make them useful in the treatment of a wide-range of skin diseases including eczema, psoriasis, atopic and contact dermatitis, according to researchers at the University of Colorado Anschutz Medical Campus. The new study app
- Sun Pharma to Present Data from Tildrakizumab Clinical Development Program at 2017 AAD Meetinghttps://practicaldermatology.com/news/sun-pharma-to-present-data-from-tildrakizumab-clinical-development-program-at-2017-aad-meeting/2458266/Sun Pharmaceutical Industries Ltd will present several new analyses from Phase-1 and the pivotal Phase-3 clinical trials (reSURFACE 1 and 2) of tildrakizumab, an investigational IL-23p19 inhibitor being evaluated for the treatment of moderate-to-severe plaque psoriasis, at the 2017 Annual America
- Vision Medical's SmartGraft Now Offers Articulating Arm With Mayo Trayhttps://practicaldermatology.com/news/vision-medicals-smartgraft-now-offers-articulating-arm-with-mayo-tray/2458276/SmartGraft® Hair Restoration is rolling out its first articulating arm and mayo tray, Vision Medical Inc., reports. Available in February, the SmartGraft AMT (articulating mayo tray) provides ergonomic design for physicians Available to ne